Corbus Pharmaceuticals to Present Phase 1a Study Results
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is poised to share exciting developments regarding its ongoing research in the treatment of obesity. The company plans to announce findings from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 before the market opens on an upcoming Thursday. A conference call and live webcast have been scheduled to take place at 8:00 am ET on the same day, where key details about the data will be discussed extensively.
Understanding CRB-913's Role
CRB-913 represents a significant advancement in obesity treatment thanks to its unique mechanism of action as an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This innovative approach is particularly noteworthy, as prior generations of related compounds have been sidelined due to concerns about potential neuropsychiatric side effects.
Unlike its predecessors, CRB-913 has been engineered to be highly peripherally restricted, which means it has minimal ability to penetrate the brain. Research indicates that CRB-913 is 15 times less likely to reach brain tissue compared to monlunabant, another CB1 inverse agonist in development. Furthermore, it demonstrates a remarkable 50-fold lower brain to plasma ratio compared to rimonabant, marking a cornerstone of safety in obesity pharmacotherapy.
The Vision of Corbus Pharmaceuticals
Corbus Pharmaceuticals is at the forefront of advancing medical solutions geared towards addressing cancer and obesity. The company is dedicated to enhancing the lives of patients confronting formidable health challenges. This commitment drives the development of innovative therapies that target well-established biological pathways. In addition to CRB-913, Corbus's pipeline includes promising candidates such as CRB-701—a next-generation antibody-drug conjugate targeting Nectin-4 on cancer cells—and CRB-601, an anti-integrin monoclonal antibody focusing on TGF? activation in cancerous tissues.
Further Communication and Engagement
While the data from the CRB-913 study is eagerly anticipated, Corbus encourages interested parties to stay connected for the latest updates. Engaging with the company via social media platforms helps provide the community with insights and fosters discussions about its medical innovations. Corbus has a prominent presence on various platforms, ensuring transparency in its efforts to combat challenges in oncology and obesity.
Frequently Asked Questions
What is CRB-913?
CRB-913 is an investigational oral medication designed to act as an inverse agonist of the CB1 receptor, targeted towards weight management.
When will Corbus report results from the Phase 1a study?
The results are expected to be announced shortly before the opening of the market on a designated Thursday.
What are the safety features of CRB-913?
CRB-913 is designed to minimize brain penetration, significantly reducing the risk of neuropsychiatric side effects associated with previous treatments.
What other products does Corbus currently develop?
Alongside CRB-913, Corbus is developing CRB-701 and CRB-601, aimed at providing innovative cancer therapies.
How can I stay updated on Corbus Pharmaceuticals?
To remain informed, engage with Corbus on their official social media channels and visit their website for the latest news.
